3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumor, Pleural
1
Seminoma
1
Sarcoma
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Paraproteinemias
1
Ovarian Neoplasms
1
Osteolysis
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Melanoma
1
Malignant Solid Tumour
1
Hypercalcemia
1
Hematologic Neoplasms
1
Fractures, Spontaneous
1
Colorectal Neoplasms
1
Carcinoma
1
Bone Diseases, Metabolic
1
Anemia
1
Amyloidosis
1
Interventions
Carboplatin
23
Cisplatin
19
pembrolizumab
14
Paclitaxel
12
Gemcitabine
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
9
Everolimus
8
Cetuximab
8
Fluorouracil
7
Axitinib
6
osimertinib
5
durvalumab
5
Sunitinib
5
Radiotherapy
5
Erlotinib Hydrochloride
5
Docetaxel
5
Cyclophosphamide
5
Albumin-Bound Paclitaxel
5
Sorafenib
4
Radiation
4
Nivolumab
4
Ipilimumab
4
vosaroxin
3
Radiotherapy, Intensity-Modulated
3
Octreotide
3
Irinotecan
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
pralsetinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma
×
ARQ 197
×
Clear all
NCT01755767
2021-04-06
METIV-HCC
Daiichi Sankyo
Phase 3
Completed
383 enrolled
17 charts